5 October 2021 in Leukemia
19 November 2021 in American Journal of Hematology
1 December 2020 in Leukemia
14 August 2021 in Blood Cancer Journal
28 July 2020 in Blood Advances
Polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes (POEMS) syndrome is associated with increased risk for ischemic stroke (IS). Because POEMS syndrome is rare, little is known regarding the underlying mechanism and prognosis for IS in patients in whom it occurs. The medical records of patients with POEMS syndrome were screened between January 2018 and January 2000 at Peking Union Medical College Hospital to identify those with IS. The baseline characteristics, IS features, and patient outcomes were analyzed. Forty-one (8.0%) of 510 POEMS patients were documented to have IS. Patients with IS were older, had a higher percentage of Overall Neuropathy Limitation Scale score >4, and had a higher level of fibrinogen compared with those who did not have IS. Ninety-three percent of IS events occurred before or within 3 months after a diagnosis of POEMS. Of 41 occurrences of IS, 29 (46.3%) were multifocal. Recurrent IS was observed in 13 (31.7%) of 41 patients, but not in patients with successful anti-plasma cell therapy. The 3-year overall survival rate in patients with IS was 71.0% and for those without IS, it was 88.5% (P = .002). We showed that 8.0% of POEMS patients had IS, and most IS events occurred in POEMS patients not being treated effectively. Having IS was a predictor of unfavorable prognosis. Early diagnosis, immediate initiation of treatment for POEMS, and control of POEMS syndrome is key to reducing the occurrence of IS, improving survival, and preventing recurrence of IS.
4 November 2023 in Transplantation and Cellular Therapy
POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndrome is a rare form of plasma cell dyscrasia often treated with high-dose chemotherapy and autologous stem cell transplantation (ASCT). ASCT has resulted in satisfactory and sustained therapeutic outcomes. However, a substantial number of patients eventually experience disease progression, requiring second-line treatment. Therefore, it would be of further benefit to identify patients who will acquire the best long-term survival after ASCT. To fully reveal the outcomes of patients receiving ASCT in a large series with long-term follow-up. Long-term outcomes of 239 patients with newly diagnosed POEMS syndrome receiving ASCT at a single center were retrospectively evaluated. Rates of hematological complete response (CRH) and VEGF (CRV) complete response were 57.3% and 68.6%, respectively, with 90.5% of patients achieving an overall clinical response. After the median follow-up time of 94 months, the 5-year OS (overall survival) rate was 92.8%, and the 5-year TTNT (time to next-line treatment) rate was 72.2% (median TTNT: 96 months). Patients achieving CRH (5-year TTNT rate 82.5% vs. 60.7%, P < 0.0001) or CRV (5-year TTNT rate 83.7% vs. 54.2%, P < 0.0001) had better survival outcomes than non-CR group patients. Dual hematological and VEGF complete responses bring further benefit for survival (median TTNT: 129 months vs. 68 months, P < 0.0001). Seven cases of second primary malignancy were recorded, all of which were solid tumors. Front-line ASCT resulted in excellent long-term survival in patients with POEMS syndrome, and the best survival was observed in those achieving dual hematological and VEGF CRs.